GS-9822

• Description :

  GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys[1].

• UNSPSC :

  12352005

• Target :

  HIV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/gs-9822.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC(C)(C)O[C@@H](C1=C(C)C=C(N=C(C2=CC=C3C(C(C4CCN(C5COC5)CC4)=NN3C)=C2)S6)C6=C1C7=CC=C(Cl)C=C7)C(O)=O

• Molecular Formula :

  C36H39ClN4O4S

• Molecular Weight :

  659.24

• References & Citations :

  [1]Bruggemans A, et al. GS-9822, a preclinical LEDGIN candidate, displays a block-and-lock phenotype in cell culture. Antimicrob Agents Chemother. 2023 May 1;65 (5) :e02328-20.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2219362-41-9]